287 related articles for article (PubMed ID: 31795143)
21. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
22. Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction.
Ciemny MP; Debinski A; Paczkowska M; Kolinski A; Kurcinski M; Kmiecik S
Sci Rep; 2016 Dec; 6():37532. PubMed ID: 27905468
[TBL] [Abstract][Full Text] [Related]
23. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
24. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
25. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
26. MDMX inhibits the p300/CBP-mediated acetylation of p53.
Sabbatini P; McCormick F
DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
[TBL] [Abstract][Full Text] [Related]
27. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
28. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides.
Brown CJ; Srinivasan D; Jun LH; Coomber D; Verma CS; Lane DP
Cell Cycle; 2008 Mar; 7(5):608-10. PubMed ID: 18256546
[TBL] [Abstract][Full Text] [Related]
29. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
[TBL] [Abstract][Full Text] [Related]
30. Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides.
Diller DJ; Swanson J; Bayden AS; Brown CJ; Thean D; Lane DP; Partridge AW; Sawyer TK; Audie J
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847417
[TBL] [Abstract][Full Text] [Related]
31. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
32. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
33. The C terminus of p53 binds the N-terminal domain of MDM2.
Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
[TBL] [Abstract][Full Text] [Related]
34. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
35. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.
Dowarha D; Chou RH; Yu C
PLoS One; 2020; 15(6):e0234152. PubMed ID: 32497081
[TBL] [Abstract][Full Text] [Related]
36. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
37. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation.
Lee CW; Ferreon JC; Ferreon AC; Arai M; Wright PE
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19290-5. PubMed ID: 20962272
[TBL] [Abstract][Full Text] [Related]
38. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
39. p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
Grossman SR; Perez M; Kung AL; Joseph M; Mansur C; Xiao ZX; Kumar S; Howley PM; Livingston DM
Mol Cell; 1998 Oct; 2(4):405-15. PubMed ID: 9809062
[TBL] [Abstract][Full Text] [Related]
40. How Does the Recently Discovered Peptide MIP Exhibit Much Higher Binding Affinity than an Anticancer Protein p53 for an Oncoprotein MDM2?
Yamada T; Hayashi T; Hikiri S; Kobayashi N; Yanagawa H; Ikeguchi M; Katahira M; Nagata T; Kinoshita M
J Chem Inf Model; 2019 Aug; 59(8):3533-3544. PubMed ID: 31282659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
